Changes in Multiple microRNA Levels with Antidepressant Treatment Are Associated with Remission and Interact with Key...

Area of Science:

• Neuroscience
• Genetics
• Pharmacology

Background:

• Individual responses to antidepressant medications like selective serotonin reuptake inhibitors (SSRIs) and mirtazapine (MIR) for major depressive disorder (MDD) vary significantly.
• The underlying molecular determinants for these differential treatment outcomes remain largely unknown.
• MicroRNA (miRNA) dysregulation is implicated in MDD pathogenesis and is being explored as a potential biomarker.

Purpose of the Study:

• To investigate plasma miRNA expression changes associated with treatment outcomes in MDD patients undergoing monotherapy with mirtazapine or an SSRI.
• To identify specific miRNAs and associated gene pathways that correlate with clinical remission after antidepressant treatment.

Main Methods:

• A 4-week randomized controlled trial involving 46 MDD patients.
• Comprehensive analysis of plasma miRNA levels before and after treatment.
• Identification of gene pathways linked to differentially expressed miRNAs.
• Database searches to compare miRNA targets with known depression-related genes and pathways.

Main Results:

• 141 plasma miRNA levels significantly correlated with treatment remission after 4 weeks of mirtazapine therapy.
• miR-1237-5p demonstrated the most robust correlation with remission.
• These miRNAs showed a negative correlation with remission, indicating a decreasing trend.
• Associated pathways included TGF-β and MAPK, with overlapping genes like MAPK1, IGF1, IGF1R, and BRAF identified.

Conclusions:

• Alterations in specific plasma miRNA levels before and after mirtazapine treatment correlate with treatment remission in MDD patients.
• The identified miRNAs and pathways represent novel findings not previously reported in relation to antidepressant treatment or MIR.
• These miRNAs may serve as potential biomarkers for predicting treatment response in MDD.